ACM
AUPH icon

ACT Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

ACT Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-51,000
Closed -$513K – 73
2022
Q2 		$513K Sell
51,000
-16,500
-24% -$184K 0.72% 25
2022
Q1 		$836K Sell
67,500
-121,000
-64% -$1.87M 0.88% 26
2021
Q4 		$4.31M Buy
188,500
+8,500
+5% +$201K 3.12% 5
2021
Q3 		$3.98M Buy
180,000
+17,500
+11% +$278K 2.06% 10
2021
Q2 		$2.11M Buy
+162,500
New +$2.07M 1.08% 22

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACT Capital Management's AUPH Position: Q3 2022 in Review

ACT Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2022, closing a stake of 51,000 shares — an estimated $513K sold.

ACT Capital Management first reported a position in AUPH in Q2 2021 and held it in 5 quarters. The position peaked at $4.31M in Q4 2021. 189 funds tracked by Wall St. Rank hold AUPH as of Q3 2022.

  • ACT Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • ACT Capital Management sold 51,000 Aurinia Pharmaceuticals shares in Q3 2022, an estimated $513K.
  • ACT Capital Management first reported a position in Aurinia Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • ACT Capital Management's Aurinia Pharmaceuticals position peaked at $4.31M in Q4 2021.
  • 189 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.